Briefing
Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial
In this phase 3 trial, 653 patients with resectable muscle-invasive bladder cancer were randomized to perioperative nivolumab plus neoadjuvant gemcitabine-cisplatin (n=325) or neoadjuvant gemcitabine-cisplatin alone (n=328). Event-free survival was not improved (HR 0.94, 95.74% CI 0.71-1.25). Pretreatment ctDNA was positive in 229 of 416 tested patients (55%), clearance by cycle 4 day 1 occurred in 153 of 199 (76.9%), and ctDNA detection at baseline and at cycle 4 day 1 was associated with shorter event-free and overall survival.
- Design: Evidence level 2
- Assay: Not named in the abstract
Annals of OncologyPubMed 42918420DOI 10.1016/j.annonc.2026.10.096